gracecastuc-026_lung_dr. wakelee on using molecular marker info for mgmt. of earlier stage nsclc
Published 11 years ago • 14 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
2:37
are molecular markers just for nsclc?
-
17:16
gracecast-028_lung-cancer_heather wakelee on nsclc adjuvant therapy
-
1:15
gracecastuc-054_lung_wakelee: my approach to repeat biopsies for adv. nsclc with insufficient tissue
-
1:50
gracecastuc-065_lung_dr. wakelee on most promising new agents and pathways for treating lung cancer
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc
-
4:29
lung resection in early stage nsclc: an overview - onctalk lung 2023
-
1:14
gracecastuc 119 lung_dr. wakelee on targeted therapies generalizable to wider range of lung cancers
-
25:07
gracecast-101_lung-cancer_mm in lc pt6: dr. goss on incorporating markers across a hc system
-
9:49
gracecast-001_lung-cancer_first line chemo for advanced nscl
-
6:11
gracecastuc-012_lung_the more you seek, the more you find
-
40:09
gracecast-076_lung-cancer_asco 2011 highlights - sclc, early stage nsclc and mesothelioma
-
7:37
gracecastuc-016_lung_a high profile failure for stimuvax: implications for future trials
-
40:44
gracecast-050_lung-cancer_ramalingam on first line therapy for advanced nsclc
-
13:40
gracecast-104_lung-cancer_immunotherapy for lung cancer: q and a session
-
12:33
gracecast-025_lung-cancer_questions and trials for nsclc
-
2:07
gracecastuc109_lung_dr. wakelee on maintenance therapy advanced nsclc
-
5:09
gracecastuc-013_lung_what should we do for a "mixed response" to lung cancer treatment?
-
5:11
gracecastuc-015_lung_what is the biology of a mixed response in lung cancer?
-
7:24
gracecastuc-025_lung_dr. riely on approach for acq. resistance to targeted therapies in adv. nsclc